Non-adherence to anti-osteoporotic medications in Taiwan: physician specialty makes a difference

被引:18
作者
Yu, Shan-Fu [1 ,2 ]
Yang, Tsong-Shing [3 ,4 ]
Chiu, Wen-Chan [1 ,2 ]
Hsu, Chung-Yuan [1 ,2 ]
Chou, Ching-Lan [1 ,2 ]
Su, Yu-Jih [1 ,2 ]
Lai, Han-Ming [1 ,2 ]
Chen, Ying-Chou [1 ,2 ]
Chen, Chung-Jen [1 ,2 ]
Cheng, Tien-Tsai [1 ,2 ]
机构
[1] Kaohsiung Chang Gung Mem Hosp, Div Rheumatol Allergy & Immunol, Dept Internal Med, Kaohsiung 833, Taiwan
[2] Chang Gung Univ, Coll Med, Kaohsiung 833, Taiwan
[3] Chiayi Chang Gung Mem Hosp, Div Rheumatol Allergy & Immunol, Dept Internal Med, Chiayi, Taiwan
[4] Chang Gung Univ, Coll Med, Chiayi, Taiwan
关键词
Osteoporosis; Medication adherence; Risk factors; Pharmacotherapy; BISPHOSPHONATE THERAPY; DRUG-THERAPY; ADHERENCE; PERSISTENCE; ALENDRONATE; MANAGEMENT; IMPACT; TRIAL; RATES; WOMEN;
D O I
10.1007/s00774-013-0424-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adherence to anti-osteoporotic regimens gradually decreases over time. We hypothesized that the determinants of non-compliance or non-persistence at different times vary and identified these differences. We used an outpatient database to retrieve information on anti-osteoporotic medications prescribed by a medical centre in southern Taiwan during 2001-2007. Compliance was defined as a medication possession ratio (MPR) a parts per thousand yen80 %. Persistence was determined as continuous use, allowing for a refill gap of 30 days. A multivariate Cox regression model evaluated potential predictors of non-adherence. A total of 3589 patients were included. In the multivariate analyses, non-compliance for both year 1 and year 2 was more likely in patients with non-vertebral non-hip fractures, respiratory disorders, prescription of the first anti-osteoporotic regimen by an orthopedist; and less likely in patients with follow-up bone densitometry and switched regimens. Risks for non-persistence at year 1 and year 2 were generally similar to those for non-compliance; insurance coverage and malignancy were associated with a lower risk of non-persistence at year 1 and year 2, respectively. In the subgroup with an MPR a parts per thousand yen80 % at year 1, an index prescription by an orthopedist was the only independent predictor of non-compliance and non-persistence at year 2. In conclusion, the positive or negative determinants of non-adherence were different at year 1 and year 2, which indicated that clinicians might deliver effective interventions to improve adherence via different precautions annually. This study also provided evidence that physician specialty had a significant effect on adherence to osteoporosis care.
引用
收藏
页码:351 / 359
页数:9
相关论文
共 35 条
[1]   Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial [J].
Black, Dennis M. ;
Schwartz, Ann V. ;
Ensrud, Kristine E. ;
Cauley, Jane A. ;
Levis, Silvina ;
Quandt, Sara A. ;
Satterfield, Suzanne ;
Wallace, Robert B. ;
Bauer, Douglas C. ;
Palermo, Lisa ;
Wehren, Lois E. ;
Lombardi, Antonio ;
Santora, Arthur C. ;
Cummings, Steven R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2927-2938
[2]   Comparison of drug adherence rates among patients with seven different medical conditions [J].
Briesacher, Becky A. ;
Andrade, Susan E. ;
Fouayzi, Hassan ;
Chan, Arnold .
PHARMACOTHERAPY, 2008, 28 (04) :437-443
[3]  
Buckley L, 2001, ARTHRITIS RHEUM, V44, P1496
[4]   The impact of compliance with osteoporosis therapy on fracture rates in actual practice [J].
Caro, JJ ;
Ishak, KJ ;
Huybrechts, KF ;
Raggio, G ;
Naujoks, C .
OSTEOPOROSIS INTERNATIONAL, 2004, 15 (12) :1003-1008
[5]   Adherence to osteoporosis medications amongst Singaporean patients [J].
Cheen, M. H. H. ;
Kong, M. C. ;
Zhang, R. F. ;
Tee, F. M. H. ;
Chandran, M. .
OSTEOPOROSIS INTERNATIONAL, 2012, 23 (03) :1053-1060
[6]   The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled [J].
Clowes, JA ;
Peel, NFA ;
Eastell, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (03) :1117-1123
[7]   Osteoporosis management: Physicians' recommendations and womens' compliance following osteoporosis testing [J].
Cole, RP ;
Palushock, S ;
Haboubi, A .
WOMEN & HEALTH, 1999, 29 (01) :101-115
[8]   Monitoring osteoporosis therapy with bone densitometry - Misleading changes and regression to the man [J].
Cummings, SR ;
Palermo, L ;
Browner, W ;
Marcus, R ;
Wallace, R ;
Pearson, J ;
Blackwell, T ;
Eckert, S ;
Black, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (10) :1318-1321
[9]   Improving the Prediction of Medication Compliance The Example of Bisphosphonates for Osteoporosis [J].
Curtis, Jeffrey R. ;
Xi, Juan ;
Westfall, Andrew O. ;
Cheng, Hong ;
Lyles, Kenneth ;
Saag, Kenneth G. ;
Delzell, Elizabeth .
MEDICAL CARE, 2009, 47 (03) :334-341
[10]  
Dawson-Hughes B, 2008, CLIN GUIDE PREVENTIO